NAL ER

Idiopathic Pulmonary Fibrosis

Clinical trials

Developer

Trevi Therapeutics

Overview

NAL ER is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 4 tracked IPF clinical trials.

NAL ER clinical trials

NCT05964335 (Phase 2)NCT04030026 (Phase 2)NCT07671911 (Phase 3)NCT07036029 (Phase 1)

Explore related

All trials Research

Medical disclaimer. This page summarizes research about NAL ER for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.